Search for a trial

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of
Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic
Angioedema with Normal C1-Inhibitor (C1-INH)

Primary: To evaluate the long-term safety of repeated subcutaneous(SC) administrations of lanadelumab in adolescents and adults with nonhistaminergicangioedema with normal C1-INH

Lanadelumab for treatment of COVID-19 disease

The objectives of this study:• To generate the proof of concept for lanadelumab for treatment of symptoms of COVID-19 disease • To demonstrate its safety after intravenous administration.